

Ħ

.





1	C	•	
1	ζ	,	
,	_	_	
į	ľ		

																													
Clade Other SEQ ID NO. E	- ,	7	m	4	8	•	7	••	Φ.	9	=	12	2	7	13	91	1	82	10	8	21	22	23	24	22	5 6	. 27	78	53
Other	××	Κ;	×				×					×	×	×	×	×	×												
Clade	×																×			×	×		×		×				
Clade D	××	× :	×				×	×	×			×	×	×	×	×	×		×						×				
Clade C	×		×									×	×	×		×			×			×							
Clade B	×	×	×	×	×	×	×			×	×	×	×	×	×	×	×		×			×		×		×	×		×
Clade A	×	×	×			•		×				×	×	×		×	×	×	×				×				•	×	
Number of Approximate Isolates Position in with Exact LAI AA sequence	gp120 - 120	gag - 215	gag - 100	RT - 354	nef - 170	nef - 170	gp120 - 30	gp120 - 452	gp120 - 20	RT - 480	gag - 263	gp120 - 420	gp120 - 420	gp120 - 215	gp120 - 446	gp120 - 215	gp120 - 420	gp120 - 275	gp41 - 175	gp120 - 215	gp120 -330		gp41 - 90		gp120 - 275	gp120 - 420	gp120 - 320		gp41 - 270
	159	36	82	17	17	16	01	×10	×10	×10	79	185	150	601	101	101	75	42	19	15	15	. 13	12	12	=======================================	0 1 0	~10	V 10	~10
Protein	Env	Sag	Gag	RT	Net.	Ze	Env	Env	Env	RT	Gag	Env	Eny	Env	Env	Env	Env	Env	Env	Env	Env	Env	Env	Tat	Env	Env	Env	Env	Env
B27 Fold Increase (less than 1.3 not											3.61		1.74													1.53	1.78		3.27
A2 Fold Increase (less than 1.3 not reported)	1.33	1.35				2.7	1.33		1.63	1.54				1.45														/	
B27 EBP.	0.00%	%; %;	%00.0	%00.0	%0.0	0.01%	%0.0	0.00%	%00.0	%00.0	14.22%	%80'66	99:52%	\$5.61%	62.11%	98.22%	91.33%	82.77%	89.06%	67.49%	56.14%	75.36%	61.09%	67.49%	59.28%	76.92%	56.93%	78.95%	89.80%
A2 EBP B27 EBP	55.68%	00.42%	62.00%	57.03%	72.52%	87.51%	76.69%	\$5.68%	90.92%				%00.0			%00.0							%00.0		%00.0	0.00%		٠.	0.01%
Sequence	KLTPLCVTLN	AEWDKVHPV	SLENTVATL	ELHPDKWTV	GMDDPEREVL	GMDDPEKEVL	HLWRWGTMLL	LLLTRDGGVN	HLWKWSTMLL	ILKEPVHGV	KRWILGLNK	CRUKOIIN	CRIKQIINMW	VSFEPIPIHF	RCSSNITGL	VSFEPIPIHY	CRIKQIVNIM	RSENITAN	REFINETY	ISPDPIPITY	YRTGDIIG	RUGPGQTFY	GCSGKIIC	RRRAPQDS	RSENITON	CRUKQFIN	KRISIGPGR	で の の の の に に の に の に に の に に に に に に に に に に に に に	GRRGWELLKY

FIG. 3

Project Outline

HLA allele selection

Indian HIV-1 sequences

EpiMatrix evaluation and selection


Binding assays (T2 stabilization)

CTL assays



Include CTL epitope in regional HIV-1 vaccine


FIG. 4 Methods: HLA allele selection



HLA-A2 and -A11, -B7 and -B35 were selected for this pilot project due their prevalence of the HLA alleles in the Indian population....

FIG. 5

Methods: HLA allele selection



... and availability of cell lines for in vitro study.

FIG. 6

EpiMatrix Predictions and Binding Results: B 7 6 out of 7, and control peptide

B7											1
peptide #	peptide # peptide seq. Used	. pesn .bes	aueB	strain	start-stop	% conserved	CTL	predicted EBP	avg MFI (200ug/ml	strain start-stop % conserved CTL predicted EBH avg MFI (200ug/mi) avg fold incr. (20ug/m	εĪ
-	RPNNNTRKSI	RPNNNTRKSI	EN	787QIQ	183-192	75	٨	%8	335.6	2.4	1
3	NPYNTPIFAL	NPYNTPIFAL	PQ.	Solnd5	61-70	9		20%	281.9	2.0	
4	RAIEAGOHLL	RAIEAGOHLL	ENS	DID747	481-490	8		17%	181.5	£.	
•6	TCKSNITGLL	TCKSNITGLL	ENS	09/010	375-384	28		18%	160.5	1,2	
	KPWSTOLL	KPWSTQLL	EN	DID747	182-191	7		46%	248.5	4,8	
	KPCVKLTPL	KPCVKLTPLC	ENS		51-60	6		27%	373.8	2.7	
	GPKVKQWPL	GPKVKQWPLT	집		25-34	5		27%	314.7	2.3	
	YPGIKVRAL	YPGIKVROLC	집	Solnd4	278-287	100		26%	378.4	2.7	٦

No In hand

FIG. 7
EpiMatrix Predictions and Binding Results: B 35
7 out of 7 ... and control peptide

B37										
p ptide #	p ptide # peptide	seq. Used	gene	strain	start-stop	% conserved	CTL	predicted EBP	avg MFI (200ug/ml)	strain start-stop % conserved CTL predicted EBH avg MFI (200ug/mi) avg fold incr. (20ug/mi)
2	TVLDVGDAYF TVLDVGDAYF	TVLDVGDAYF	Pol	Solnd4	114-123	100	Υ	4%	47.9	1.8
9	EPPFLWMGY	EPPFLWMGYE	ğ	Solnd4	231-239	100		% 6	48.7	4.8
_	VPVKLKPGM	VPVKLKPGMD	Š Ž	Solnd4	15-24	100		% 6	53.3	1.7
- 60		CPKVTFDPIP	EN	DID760	144-153	53		7%	35.0	1.2
	KPWSTQLL	KPWSTQLL	EN	DID747	182-191	7		%6	40.5	4.
	KPCVKLTPL	KPCVKLTPLC	ENS	DID747	51-60	100		11%	52.1	1.7
	GPKVKQWPL	GPKVKQWPLT	전	Solnd4	25-34	5		11%	41.2	4.4
		YPGIKVROLC	<u>ठ</u>	POL Solnd4	278-287	100		7%	40.7	1,3

FIG. 8
EpiMatrix Predictions and Binding Results: A 2
3 out of 7 ... and control peptide

43										
2				,						
peptide #	peptide	seq. Used	aueß.	strain	start-stop	% conserved	CTL	predicted EBP	avg MFI (200ug/ml)	strain start-stop % conserved CTL predicted EBH avg MFI (200ug/ml) avg fold incr. (20ug/ml
13	ILKEPVHGV	ILKEPVHGVY	POL	Solnd4 316-325	316-325	80	>	%98	1604.2	1.6
14	QLPEKDSWTV	OLPEKDSWTV QLPEKDSWTV	POL	Soind4	252-261	100		87%	1368.1	1.4
13	NLWTVYYGV NLWTVYYGV	NLWTVYYGV	EN	GrD1024 32-41	32-41	67		84%	1716.9	. **
16	QMHEDVISL	QMHEDVISLW		DID747	37-46	91		78%	1413.1	4.
11	KIEELREHLL	KIEELREHLL	전	Solnd5	208-217	80		79%	889.9	6.0
18	DMVNQMHEDV	DMVNQMHEDV DMVNQMHEDV	ENS	DID747	33-42	2		77%	731.1	9.0
18	GLKKKKSVTV GLKKKKSVTV	GLKKKKSVTV	og G	Solnd4	106-115	100		78%	1088.4	7:
20	ELHPDKWTV	ELHPDKWTV ELHPDKWTVQ	POL 8	olnd4	240-249	80		72%	1048.1	0,1

FIG. 9

EpiMatrix Predictions and Binding Results: A 11
4 out of 7 ... and control peptide

A11										
peptide #	peptide	seq. Used	gene	strain	start-stop	% conserved	F	start-stop % conserved CTL predicted EBP avg I	avg MFI (200ug/ml)	MFI (200ug/ml) avg fold incr. (20ug/ml,
21	IYQEPFKNLK	IYQEPFKNLK	POL	Solnd4	348-357	100	>	%/	677.5	3.1
22	VTFDPIPIHY	VTFDPIPIHY	ENV	09/010	147-158	53		22%	190.0	6.0
23	TVQCTHGIK	TVQCTHGIKP	EN	DID747	174-183	28		44%	733.4	3.3
24	NTPIFALKKK	NTPIFALKKK	^Z	SolndS	64-73	09		44%	. 187.8	0.0
28	LVDFRELNK	LVDFRELNKR	ᅙ	Solnd4	81-90	100		47%	755.2	4.6
5 8	PGMDGPKVK	PGMDGPKVKQ	P _Q	Solnd4	21-30	5		52%	193.8	. 2.0
72	GIPHPAGLKK	GIPHPAGLKK	집	Solnd4	100-109	100		62%	308.6	4:
28	FTTPDKKHOK FTTPDKKHOK	FTTPOKKHOK	절	Solnd4	221-330	100		63%	920.6	1.4

FIG. 10

Methods: T2 Binding Assay

TAP deficient cells. The stabilized MHC-peptide complex is detected Allele matched peptides stabilize MHC molecules on the surface of using Ab to the MHC and fluorescence labeled secondary Ab.





FIG. 11

Clustering of putative MHC ligands in env



This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.